Ebooks | Diaceutics

Ebooks

Our Ebooks cover a range of essential topics that can help you to build corporate knowledge on targeted therapy and companion diagnostic commercialization
June 30th, 2017
Better Testing
A shift to value-based pricing for drugs in the US market has been much anticipated by payers and the pharma industry alike. However, better testing has not featured adequately in the debate to date. This Ebook contains articles and discussion from Diaceutics on how better testing can play a central role in achieving the optimal economic model.
April 4th, 2017
Pharma Readiness for Diagnostic Integration 2017
Being at the heart of the diagnostics space, Diaceutics is perfectly placed to not only analyse and comment on the precision medicine world in real-time but to make informed and thought-provoking predictions for the years ahead. This collection of opinion pieces written for Pharma Readiness for Diagnostic Integration 2017 looks at the key trends likely to shape the pharma/diagnostic interface ...
October 14th, 2016
Personalized Medicine: What Pharma Should Do To Get Ready
An essential component of personalized medicine is diagnostic (Dx) testing, which identifies the right patient for the right drug. The diagnostic industry is growing steadily, but what does it mean for the pharmaceutical industry and how can pharma seize this personalized medicine opportunity?
September 16th, 2016
Regulatory Matters in Personalized Medicine
Regulation of personalized medicine therapies and diagnostics is essential but often lengthy and complex. Learn more about particular regulatory aspects by downloading our Ebook.
August 9th, 2016
The Challenges of Access and Reimbursement
Access to diagnostic tests and the subsequent reimbursement is an issue affecting all stakeholders in personalized medicine. Learn more about these challenges and how to overcome them by downloading our Ebook.
May 10th, 2016
How Diagnostics are Changing Pharma Launches
Pharma is moving away from launching with the one-size-fits-all model of drug launches towards multiple, smaller launches in personalized medicine due to ever diminishing return on investment (ROI). Learn how to understand, overcome and master diagnostic launches by downloading our Ebook right now.

Latest Blogs

Blogs

Webinars & Podcasts

August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
April 20th, 2018
Podcast: PM Readiness Report 2018
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.

Publications

September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
August 3rd, 2018
A Way Forward: Leveraging Advanced Diagnostic Testing to Unlock the Value of Precision Medicine
Read about how advanced diagnostic testing, ensuring that right patient gets the right therapy, at the right time, particularly with respect to therapies where the test result determines whether or not the therapy should be used (precision medicin...

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
June 30th, 2017
Better Testing
A shift to value-based pricing for drugs in the US market has been much anticipated by payers and the pharma industry alike. However, better testing has not featured adequately in the debate to date. This Ebook contains articles and discussion from Diaceutics on how better testing can play a central role in achieving the optimal economic model.
April 4th, 2017
Pharma Readiness for Diagnostic Integration 2017
Being at the heart of the diagnostics space, Diaceutics is perfectly placed to not only analyse and comment on the precision medicine world in real-time but to make informed and thought-provoking predictions for the years ahead. This collection of opinion pieces written for Pharma Readiness for Diagnostic Integration 2017 looks at the key trends likely to shape the pharma/diagnostic interface ...
October 14th, 2016
Personalized Medicine: What Pharma Should Do To Get Ready
An essential component of personalized medicine is diagnostic (Dx) testing, which identifies the right patient for the right drug. The diagnostic industry is growing steadily, but what does it mean for the pharmaceutical industry and how can pharma seize this personalized medicine opportunity?
September 16th, 2016
Regulatory Matters in Personalized Medicine
Regulation of personalized medicine therapies and diagnostics is essential but often lengthy and complex. Learn more about particular regulatory aspects by downloading our Ebook.
August 9th, 2016
The Challenges of Access and Reimbursement
Access to diagnostic tests and the subsequent reimbursement is an issue affecting all stakeholders in personalized medicine. Learn more about these challenges and how to overcome them by downloading our Ebook.
May 10th, 2016
How Diagnostics are Changing Pharma Launches
Pharma is moving away from launching with the one-size-fits-all model of drug launches towards multiple, smaller launches in personalized medicine due to ever diminishing return on investment (ROI). Learn how to understand, overcome and master diagnostic launches by downloading our Ebook right now.
September 29th, 2017
PD-L1: The Story So Far
PD-L1 has been one of the most talked about new biomarkers in the context of targeted therapy. This Ebook looks at the dynamic PD-L1 space and discusses topics such as test availability, integration alongside more established biomarkers, complementary testing and how a suboptimal PD-L1 diagnostic marketplace can lead to lost treatment opportunities.
June 30th, 2017
Better Testing
A shift to value-based pricing for drugs in the US market has been much anticipated by payers and the pharma industry alike. However, better testing has not featured adequately in the debate to date. This Ebook contains articles and discussion from Diaceutics on how better testing can play a central role in achieving the optimal economic model.
April 4th, 2017
Pharma Readiness for Diagnostic Integration 2017
Being at the heart of the diagnostics space, Diaceutics is perfectly placed to not only analyse and comment on the precision medicine world in real-time but to make informed and thought-provoking predictions for the years ahead. This collection of opinion pieces written for Pharma Readiness for Diagnostic Integration 2017 looks at the key trends likely to shape the pharma/diagnostic interface ...
October 14th, 2016
Personalized Medicine: What Pharma Should Do To Get Ready
An essential component of personalized medicine is diagnostic (Dx) testing, which identifies the right patient for the right drug. The diagnostic industry is growing steadily, but what does it mean for the pharmaceutical industry and how can pharma seize this personalized medicine opportunity?
September 16th, 2016
Regulatory Matters in Personalized Medicine
Regulation of personalized medicine therapies and diagnostics is essential but often lengthy and complex. Learn more about particular regulatory aspects by downloading our Ebook.
August 9th, 2016
The Challenges of Access and Reimbursement
Access to diagnostic tests and the subsequent reimbursement is an issue affecting all stakeholders in personalized medicine. Learn more about these challenges and how to overcome them by downloading our Ebook.
May 10th, 2016
How Diagnostics are Changing Pharma Launches
Pharma is moving away from launching with the one-size-fits-all model of drug launches towards multiple, smaller launches in personalized medicine due to ever diminishing return on investment (ROI). Learn how to understand, overcome and master diagnostic launches by downloading our Ebook right now.

Blogs

Webinars & Podcasts

August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
April 20th, 2018
Podcast: PM Readiness Report 2018
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.

Publications

September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
August 3rd, 2018
A Way Forward: Leveraging Advanced Diagnostic Testing to Unlock the Value of Precision Medicine
Read about how advanced diagnostic testing, ensuring that right patient gets the right therapy, at the right time, particularly with respect to therapies where the test result determines whether or not the therapy should be used (precision medicin...

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
Facebook
Twitter
YouTube
LinkedIn